CBER's Peter Marks shares pandemic lessons as FDA continues 'going through the backlog'
The FDA will likely take the rest of this calendar year to catch up on a backlog of work that was set aside during the Covid-19 pandemic, CBER director Peter Marks said Monday at the 2023 BIO conference.
Marks noted there’s “an awful lot to catch up on” as the agency emerges from the pandemic, pointing out the push for RSV vaccines as well as vaccines for tropical illnesses. The agency also racked up a backlog of inspections amid the pandemic that grew into the thousands, though CDER director Patrizia Cavazzoni said back in June that regulators had caught up on domestic pre-approval inspections, according to a report from RAPS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
